BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 12947072)

  • 1. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.
    Hwu WJ; Krown SE; Menell JH; Panageas KS; Merrell J; Lamb LA; Williams LJ; Quinn CJ; Foster T; Chapman PB; Livingston PO; Wolchok JD; Houghton AN
    J Clin Oncol; 2003 Sep; 21(17):3351-6. PubMed ID: 12947072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study.
    Hwu WJ; Lis E; Menell JH; Panageas KS; Lamb LA; Merrell J; Williams LJ; Krown SE; Chapman PB; Livingston PO; Wolchok JD; Houghton AN
    Cancer; 2005 Jun; 103(12):2590-7. PubMed ID: 15861414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.
    Hwu WJ; Panageas KS; Menell JH; Lamb LA; Aird S; Krown SE; Williams LJ; Chapman PB; Livingston PO; Wolchok JD; Houghton AN
    Cancer; 2006 Jun; 106(11):2445-51. PubMed ID: 16639739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial.
    Hwu WJ; Krown SE; Panageas KS; Menell JH; Chapman PB; Livingston PO; Williams LJ; Quinn CJ; Houghton AN
    J Clin Oncol; 2002 Jun; 20(11):2610-5. PubMed ID: 12039921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
    Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC
    Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
    Danson S; Lorigan P; Arance A; Clamp A; Ranson M; Hodgetts J; Lomax L; Ashcroft L; Thatcher N; Middleton MR
    J Clin Oncol; 2003 Jul; 21(13):2551-7. PubMed ID: 12829675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102).
    Krown SE; Niedzwiecki D; Hwu WJ; Hodgson L; Houghton AN; Haluska FG;
    Cancer; 2006 Oct; 107(8):1883-90. PubMed ID: 16986123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma.
    García M; del Muro XG; Tres A; Crespo C; Valladares M; López JJ; Rifà J; Pérez X; Filipovich E; Germà-Lluch JR
    Melanoma Res; 2006 Aug; 16(4):365-70. PubMed ID: 16845333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma.
    Weber RW; O'Day S; Rose M; Deck R; Ames P; Good J; Meyer J; Allen R; Trautvetter S; Timmerman M; Cruickshank S; Cook M; Gonzalez R; Spitler LE
    J Clin Oncol; 2005 Dec; 23(35):8992-9000. PubMed ID: 16260693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study.
    Atkins MB; Sosman JA; Agarwala S; Logan T; Clark JI; Ernstoff MS; Lawson D; Dutcher JP; Weiss G; Curti B; Margolin KA
    Cancer; 2008 Oct; 113(8):2139-45. PubMed ID: 18792064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma.
    Tarhini AA; Kirkwood JM; Gooding WE; Moschos S; Agarwala SS
    Cancer; 2008 Oct; 113(7):1632-40. PubMed ID: 18720480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group.
    Bafaloukos D; Gogas H; Georgoulias V; Briassoulis E; Fountzilas G; Samantas E; Kalofonos Ch; Skarlos D; Karabelis A; Kosmidis P
    J Clin Oncol; 2002 Jan; 20(2):420-5. PubMed ID: 11786569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508.
    Clark JI; Moon J; Hutchins LF; Sosman JA; Kast WM; Da Silva DM; Liu PY; Thompson JA; Flaherty LE; Sondak VK
    Cancer; 2010 Jan; 116(2):424-31. PubMed ID: 19918923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study.
    Agarwala SS; Kirkwood JM; Gore M; Dreno B; Thatcher N; Czarnetski B; Atkins M; Buzaid A; Skarlos D; Rankin EM
    J Clin Oncol; 2004 Jun; 22(11):2101-7. PubMed ID: 15169796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma.
    Laber DA; Okeke RI; Arce-Lara C; Taft BS; Schonard CL; McMasters KM; Kloecker GH; Miller DM
    J Cancer Res Clin Oncol; 2006 Sep; 132(9):611-6. PubMed ID: 16741726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study.
    Agarwala SS; Kirkwood JM
    Cancer; 2003 Jan; 97(1):121-7. PubMed ID: 12491513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma.
    Larkin JM; Hughes SA; Beirne DA; Patel PM; Gibbens IM; Bate SC; Thomas K; Eisen TG; Gore ME
    Br J Cancer; 2007 Jan; 96(1):44-8. PubMed ID: 17146474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF.
    Lewis KD; Gibbs P; O'Day S; Richards J; Weber J; Anderson C; Zeng C; Baron A; Russ P; Gonzalez R
    Cancer Invest; 2005; 23(4):303-8. PubMed ID: 16100942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temozolomide and interferon alpha 2b in metastatic melanoma stage IV.
    Richtig E; Hofmann-Wellenhof R; Pehamberger H; Forstinger Ch; Wolff K; Mischer P; Raml J; Fritsch P; Zelger B; Ratzinger G; Koller J; Lang A; Konrad K; Kindermann-Glebowski E; Seeber A; Steiner A; Fialla R; Pachinger W; Kos C; Klein G; Kehrer H; Kerl H; Ulmer H; Smolle J
    Br J Dermatol; 2004 Jul; 151(1):91-8. PubMed ID: 15270876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma.
    Kim KB; Hwu WJ; Papadopoulos NE; Bedikian AY; Camacho LH; Ng C; Hernandez IM; Frost AM; Jack MA; Hwu P
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):161-7. PubMed ID: 19002462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.